CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

Following a roadshow with institutional investors via several virtual conferences, Cheplapharm has priced €575 million of its 4.375% senior secured notes due 2028 and $500 million of its 5.500% senior secured notes due 2028 (the “Notes”). The final orderbook was multiple times oversubscribed.

Cheplapharm intends to use the proceeds from the Notes offering towards paying the purchase price for several marketing authorizations for certain medicinal products it agreed to acquire between June and September 2020 and costs and expenses related to the foregoing.

“I am very proud of the massive response we have received from investors in Europe and the United States.” states Sebastian F. Braun (CEO) after the pricing of the Notes.

“This transaction ensures that we are able to make a huge step forward in achieving our ambitious goals for this year. Our banks and lawyers did a great job during this transaction” added Jens Rothstein (CFO).

The Dollar tranche ensures an even higher flexibility for Cheplapharm’s business activities and shows Cheplapharm’s commitment to further optimizing, diversifiying and sustainably securing its long-term debt structure. The new financing structure offers Cheplapharm increased flexibility at attractive conditions.

Investor Relations topics

Back to top expand_less